These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32564750)

  • 1. Fluoroquinolones: Blessings Or Curses.
    Majalekar PP; Shirote PJ
    Curr Drug Targets; 2020; 21(13):1354-1370. PubMed ID: 32564750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antibacterial activity of fluoroquinolone derivatives: An update (2018-2021).
    Jia Y; Zhao L
    Eur J Med Chem; 2021 Nov; 224():113741. PubMed ID: 34365130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of the fluoroquinolones: focus on levofloxacin.
    Liu HH
    Drug Saf; 2010 May; 33(5):353-69. PubMed ID: 20397737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
    Hoepelman I
    Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety profile of the fluoroquinolones.
    Bertino J; Fish D
    Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fluoroquinolone antibacterials: past, present and future perspectives.
    Appelbaum PC; Hunter PA
    Int J Antimicrob Agents; 2000 Sep; 16(1):5-15. PubMed ID: 11185413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals.
    Yarrington ME; Anderson DJ; Dodds Ashley E; Jones T; Davis A; Johnson M; Lokhnygina Y; Sexton DJ; Moehring RW
    Infect Control Hosp Epidemiol; 2019 Nov; 40(11):1297-1300. PubMed ID: 31474240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
    Puig C; Tirado-Vélez JM; Calatayud L; Tubau F; Garmendia J; Ardanuy C; Marti S; de la Campa AG; Liñares J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):461-6. PubMed ID: 25385097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quinolones: decades of development and use.
    Emmerson AM; Jones AM
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():13-20. PubMed ID: 12702699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schematic-portfolio of potent anti-microbial scaffolds targeting DNA gyrase: Unlocking ways to overcome resistance.
    Pakeeraiah K; Mal S; Mahapatra M; Mekap SK; Sahu PK; Paidesetty SK
    Int J Biol Macromol; 2024 Jan; 256(Pt 2):128402. PubMed ID: 38035955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.